ReviewPain medicine (Malden, Mass.)2026
Topical analgesics for neuropathic pain: an evidence-informed guide for the practicing clinician.
Review in Pain medicine (Malden, Mass.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Functional and molecular diversity of human C-fibers in pain modulation.Current opinion in supportive and palliative care · 2026Review
- Procedural Optimization of Capsaicin 8% Patch Therapy Using Ultrasound-Guided Bilateral Ankle Nerve Block in Painful Diabetic Peripheral Neuropathy: A Retrospective Comparative Cohort Study.Healthcare (Basel, Switzerland) · 2026Article
- Topical Pain Management: An Updated Review of Current Evidence and Emerging Strategies.Journal of clinical medicine · 2026Review
- Topical Pregabalin in Burning Mouth Syndrome: A Real-World Study of Peripheral Neuromodulation.Medicina (Kaunas, Lithuania) · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
objectiveTo evaluate available evidence for the efficacy and safety of topical analgesics for neuropathic pain and to offer treatment guidance.
methodsAn expert panel searched PubMed (Medline) and reference lists of published articles for available literature assessing 8 categories of topical analgesics used to treat various neuropathic pain conditions. The panel rated the level of analgesic efficacy evidence for each treatment and considered safety, ease of use, and cost. The degree of consensus on the recommendations among the panelists was measured.
resultsThere was strong evidence and high consensus that capsaicin 8% is effective for diabetic peripheral neuropathy and postherpetic neuralgia and that lidocaine is effective for postherpetic neuralgia. There was strong evidence and moderate consensus that capsaicin 8% could be effective for HIV-induced neuropathy. There was moderate evidence and high consensus that lidocaine is likely effective for diabetic peripheral neuropathy, idiopathic neuropathy, and postsurgical neuropathy and that capsaicin 8% might be effective for chemotherapy-induced peripheral neuropathy and complex regional pain syndrome. Evidence was weak for other topical medications, though the panel strongly agreed that antidepressants might help with postherpetic neuralgia, complex regional pain syndrome, postsurgical neuropathy, and post-traumatic neuropathy; that nonsteroidal anti-inflammatory drugs could help with postsurgical neuropathy; and that gabapentin might benefit vulvodynia. There was less agreement about whether antidepressants might benefit diabetic peripheral neuropathy, chemotherapy-induced peripheral neuropathy, and vulvodynia and whether capsaicin 8% could be effective for postsurgical neuropathy.
conclusionsRecommendations were based on a survey and grading of existing literature and, when strong evidence was lacking, the collective clinical expertise of panelists.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.